Reviewer's report 
 Antiviral Therapy In Neonatal Cholestatic Cytomegalovirus Hepatitis Title: 
 3  22 July 2006 Version: Date: 
 Philip Rosenthal Reviewer: 
Reviewer's report: 
General 
------------------------------------------------------------------------------- 
Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached) 
None 
------------------------------------------------------------------------------- Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct) 
There are numerous English spelling errors and grammatical errors. This current form of the manuscript will
be greatly improved by someone more familiar with English who revises the manuscript. ------------------------------------------------------------------------------- Discretionary Revisions (which the author can choose to ignore) 
None 
 Accept after minor essential revisions What next?: 
 An article whose findings are important to those with closely related research interests Level of interest: 
 Needs some language corrections before being published Quality of written English: 
 No Statistical review: 
Declaration of competing interests: 
I have received research support from Roche Laboratories who make ganciclovir. 
Reviewer's report 
 Antiviral Therapy In Neonatal Cholestatic Cytomegalovirus Hepatitis Title: 
 3  22 July 2006 Version: Date: 
 Philip Rosenthal Reviewer: 
Reviewer's report: 
General 
------------------------------------------------------------------------------- 
Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached) 
None 
------------------------------------------------------------------------------- Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct) 
There are numerous English spelling errors and grammatical errors. This current form of the manuscript will
be greatly improved by someone more familiar with English who revises the manuscript. ------------------------------------------------------------------------------- Discretionary Revisions (which the author can choose to ignore) 
None 
 Accept after minor essential revisions What next?: 
 An article whose findings are important to those with closely related research interests Level of interest: 
 Needs some language corrections before being published Quality of written English: 
 No Statistical review: 
Declaration of competing interests: 
I have received research support from Roche Laboratories who make ganciclovir. 
Please review this paper.
user
Reviewer's report 
 Antiviral Therapy In Neonatal Cholestatic Cytomegalovirus Hepatitis Title: 
 3  22 July 2006 Version: Date: 
 Philip Rosenthal Reviewer: 
Reviewer's report: 
General 
------------------------------------------------------------------------------- 
Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached) 
None 
------------------------------------------------------------------------------- Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct) 
There are numerous English spelling errors and grammatical errors. This current form of the manuscript will
be greatly improved by someone more familiar with English who revises the manuscript. ------------------------------------------------------------------------------- Discretionary Revisions (which the author can choose to ignore) 
None 
 Accept after minor essential revisions What next?: 
 An article whose findings are important to those with closely related research interests Level of interest: 
 Needs some language corrections before being published Quality of written English: 
 No Statistical review: 
Declaration of competing interests: 
I have received research support from Roche Laboratories who make ganciclovir. 
assistant